Rapid Mycoplasma Testing vs Traditional Methods: Which Is Better for ATMPs?

Advanced Therapy Medicinal Products (ATMPs) are transforming modern healthcare through innovative treatments such as cell therapies, gene therapies, and tissue-engineered products. As these therapies move toward commercialization, maintaining strict quality and safety standards becomes increasingly important. One of the biggest concerns in ATMP manufacturing is microbial contamination, especially mycoplasma contamination, which can compromise product quality, patient safety, and regulatory compliance.

Because of this risk, reliable mycoplasma detection and robust sterility testing strategies are essential throughout the manufacturing process. However, manufacturers often face a critical question: should they rely on traditional testing methods or adopt rapid mycoplasma testing technologies?

Understanding the Risk of Mycoplasma Contamination

Mycoplasmas are small bacteria that lack a cell wall, making them difficult to identify through standard microscopy. They can spread quickly in cell culture systems without visible signs of contamination. In ATMP manufacturing, even low levels of contamination may affect cell viability, alter genetic stability, and impact therapeutic efficacy.

Effective mycoplasma detection is therefore a key component of quality control in advanced therapy manufacturing. Detecting contamination early helps manufacturers prevent costly batch failures and ensures compliance with regulatory requirements.

In facilities using advanced production platforms such as scale ready g rex systems, contamination control becomes even more critical because these systems are designed for scalable and high-density cell expansion.

Traditional Mycoplasma Testing Methods

Traditional mycoplasma testing methods have been widely used for decades and remain accepted by global regulatory authorities. Common approaches include culture-based testing and DNA staining methods.

Culture-Based Testing

Culture methods involve growing mycoplasma organisms in specialized media under controlled conditions. This technique is highly sensitive and capable of detecting a broad range of species. However, the process is time-consuming and can take up to 28 days to deliver results.

For ATMP manufacturers operating under tight production timelines, this delay may create logistical challenges, especially when dealing with short shelf-life products.

Indicator Cell Culture and DNA Staining

Another traditional method involves co-culturing samples with indicator cells and using fluorescent DNA stains to identify contamination. While this approach is effective, it also requires experienced personnel and extended incubation periods.

Although traditional methods are reliable, they are not always ideal for fast-paced ATMP manufacturing environments where rapid product release is essential.

The Rise of Rapid Mycoplasma Testing

To address the limitations of conventional approaches, many manufacturers are turning to rapid testing technologies. These methods use advanced molecular biology techniques such as PCR and nucleic acid amplification to identify contamination within hours instead of weeks.

Rapid testing has become increasingly important for Sterility testing for ATMPs because many cell therapy products cannot wait for long incubation periods before release.

Advantages of Rapid Testing

Faster Turnaround Time

The biggest advantage of rapid methods is speed. Results can often be obtained within the same day, helping manufacturers make faster release decisions and reduce production delays.

Improved Manufacturing Efficiency

Rapid testing supports continuous manufacturing operations and helps facilities optimize workflow efficiency. This is particularly beneficial in automated and scalable systems such as scale ready g rex platforms, where maintaining uninterrupted production is critical.

Reduced Risk of Batch Failure

Early contamination detection allows manufacturers to take corrective action before contamination spreads across production batches. This minimizes financial losses and protects valuable therapeutic materials.

Better Support for Short Shelf-Life Products

Many ATMPs have limited storage stability and require immediate release after manufacturing. Rapid testing enables manufacturers to meet these timelines while maintaining compliance with Sterility testing for ATMPs requirements.

Challenges of Rapid Testing

Despite its advantages, rapid mycoplasma testing also presents certain challenges.

Regulatory Validation

Manufacturers must demonstrate that rapid methods are equivalent or superior to traditional compendial methods. This requires extensive validation and documentation before regulatory approval.

Equipment and Training Costs

Rapid molecular testing systems often require specialized instruments and trained personnel. Initial implementation costs may be higher compared to conventional methods.

Limited Detection Scope

Some rapid assays may not detect all mycoplasma species with equal sensitivity. Therefore, manufacturers must carefully select validated assays suitable for their specific applications.

Which Method Is Better for ATMPs?

The answer depends on the manufacturing strategy, product type, and regulatory requirements. Traditional methods remain valuable because of their proven reliability and regulatory acceptance. However, rapid methods provide significant operational advantages for modern ATMP production environments.

For many manufacturers, a hybrid approach offers the best solution. Rapid methods can support in-process monitoring and faster decision-making, while traditional methods can serve as confirmatory tests for regulatory compliance.

As ATMP manufacturing continues to evolve, the demand for faster and more efficient quality control solutions will continue growing. Advanced manufacturing platforms such as scale ready g rex systems are helping companies scale production, but they also require equally advanced contamination monitoring strategies.

Reliable mycoplasma detection technologies combined with comprehensive Sterility testing for ATMPs help manufacturers maintain product quality, improve efficiency, and protect patient safety throughout the production lifecycle.

Conclusion

The future of ATMP manufacturing depends on balancing speed, scalability, and regulatory compliance. While traditional mycoplasma testing methods remain important, rapid testing technologies are becoming increasingly valuable in modern manufacturing workflows.

By implementing effective mycoplasma detection strategies and integrating advanced Sterility testing for ATMPs protocols, manufacturers can reduce contamination risks and accelerate product release timelines. As scalable production systems like scale ready g rex continue gaining adoption, rapid and reliable quality testing will play a critical role in supporting the safe commercialization of advanced therapies.